CA2262007A1 - Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii - Google Patents

Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii Download PDF

Info

Publication number
CA2262007A1
CA2262007A1 CA002262007A CA2262007A CA2262007A1 CA 2262007 A1 CA2262007 A1 CA 2262007A1 CA 002262007 A CA002262007 A CA 002262007A CA 2262007 A CA2262007 A CA 2262007A CA 2262007 A1 CA2262007 A1 CA 2262007A1
Authority
CA
Canada
Prior art keywords
htlv
protein
env
subject
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002262007A
Other languages
English (en)
Inventor
William W. Hall
Hidehiro Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2262007A1 publication Critical patent/CA2262007A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des nouveaux antigènes protéiniques, dérivés de la protéine d'enveloppe de HTLV (virus du lymphome humain à lymphocytes T), que l'on peut utiliser en tant que vaccin dans la prévention et le traitement d'infections à HTLV-I et HTLV-II; elle concerne également des nouveaux procédés de production d'un tel antigène.
CA002262007A 1996-07-22 1997-07-22 Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii Abandoned CA2262007A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68105496A 1996-07-22 1996-07-22
US08/681,054 1996-07-22
US89789897A 1997-07-21 1997-07-21
US08/897,898 1997-07-21
PCT/US1997/012776 WO1998003197A1 (fr) 1996-07-22 1997-07-22 Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii

Publications (1)

Publication Number Publication Date
CA2262007A1 true CA2262007A1 (fr) 1998-01-29

Family

ID=27102582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002262007A Abandoned CA2262007A1 (fr) 1996-07-22 1997-07-22 Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii

Country Status (4)

Country Link
EP (1) EP0942748A4 (fr)
JP (1) JP2002513381A (fr)
CA (1) CA2262007A1 (fr)
WO (1) WO1998003197A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648926B1 (fr) * 2003-05-02 2013-07-03 Centre National De La Recherche Scientifique (Cnrs) Glut-1 comme récepteur d'enveloppes htlv et son utilisation
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2010079208A1 (fr) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique Nouveaux ligands de liaison de récepteur, et leur utilisation dans la détection de cellules ayant un intérêt biologique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743678A (en) * 1983-04-27 1988-05-10 President And Fellows Of Harvard College Method and products for detection of human T cell leukemia virus
US5516632A (en) * 1988-02-08 1996-05-14 Duke University Synthetic peptides

Also Published As

Publication number Publication date
EP0942748A4 (fr) 2004-12-08
JP2002513381A (ja) 2002-05-08
WO1998003197A1 (fr) 1998-01-29
EP0942748A1 (fr) 1999-09-22

Similar Documents

Publication Publication Date Title
US5580773A (en) Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
JP4278293B2 (ja) Ｈｉｖの増殖を抑える方法及び組成物
US5643756A (en) Fusion glycoproteins
US5955342A (en) Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5840313A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Luo et al. Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells
US6544752B1 (en) Anigenically-marked non-infectious retrovirus-like particles
EP0550599B1 (fr) Peptides destines a etre utilises dans la vaccination et dans l'induction d'anticorps neutralisants pour lutter contre le virus d'immunodeficience humaine
WO1991000904A1 (fr) EXPRESSION DE LA PROTEINE gag DE RETROVIRUS DANS DES CELLULES EUCARYOTIQUES
JP2002533125A (ja) 改変ｈｉｖｅｎｖポリペプチド
EP0577894B1 (fr) Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques
KR19990044093A (ko) 다수-서브타입 ｆｉｖ 백신
EP0740792B1 (fr) Peptomeres a immunogenicite accrue
WO1994000562A1 (fr) Nouveau virus d'immunodeficience humaine
JPH11515006A (ja) ヒト免疫不全ウイルス感染の予防用合成ワクチン
Erturk et al. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection
JPH09512561A (ja) ヒト免疫不全ウイルス感染に対する防御用合成ワクチン
Charbit et al. Immunogenicity and antigenicity of conserved peptides from the envelope of HIV-1 expressed at the surface of recombinant bacteria
WO1998003197A9 (fr) Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii
WO1998003197A1 (fr) Vaccin a base de glycoproteine d'enveloppe destine a proteger contre l'infection a htlv-i et htlv-ii
US5516632A (en) Synthetic peptides
US20050025779A1 (en) HIV-1 envelope glycoproteins having unusual disulfide structure
EP0693938B1 (fr) Peptides utilises pour la vaccination et pour l'induction d'anticorps neutralisants diriges contre le virus d'immunodeficience humaine
EP0328390B1 (fr) Traitement aux peptides de maladies infectieuses rebelles
WO1999051268A9 (fr) Compositions immunomodulatoires d'antigenes mmtv et leurs techniques d'application

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050722